Investor Presentaiton
DONESTAⓇ: potentially beyond VMS
Clinical Phase
Phase 3
Phase 2
Primary Endpoint
Estetrol effect on reducing
Vaso-Motor Symptom
frequency / severity, H & NH*
women
Estetrol effect on various aspects of
Female Sexual and Urogenital
Functions
Secondary Endpoint
Effect on lipids, glucose metabolism, hemostasis parameters,
breast density endometrial safety, health-related quality of life,
treatment satisfaction and vulvar and vulvo-vaginal atrophy
Effect of Estetrol on quality of life
Phase 2
Effect of Estetrol on skin
health, quality and
appearance
Phase 2
Effect of Estetrol on quality of life and various skin-related
endpoints
Effect of Estetrol on hair
texture, quality and
appearance
Effect of Estetrol on quality of life and various hair-related
endpoints
*Hysterectomized and non-hysterectomized
Published Phase 2 data: Gaspard et al., Menopause 2023 in press; Gaspard et al., Menopause 2020; Douxfils et al., Climacteric 2022
Mithra Investor Presentation November 2023
24View entire presentation